Caroline Connor's concerns about her son's development began around his first birthday, when she noticed he wasn't talking or using any words. Their pediatrician didn't seem worried, but the speech delay persisted. At 2½, ...
Sep 29, 2025
0
23
In a small, investigator-initiated Phase II study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed notable activity in pre-treated ...
Apr 5, 2024
0
44
Updated dose expansion data of the phase I STRO-002-GM1 study have been presented today by Ana Oaknin, Principal Investigator of the Vall d'Hebron Institute of Oncology's (VHIO) Gynecological Malignancies Group, on the ground ...
Jun 3, 2023
0
52
An innovative cancer drug discovered by scientists at The Institute of Cancer Research, London, is set to enter a new clinical trial.
May 5, 2023
0
92
In an internationally conducted clinical trial lead by Dana-Farber involving patients with recurrent ovarian cancer that is resistant to platinum therapy, a novel conjugate therapy called mirvetuximab soravtansine resulted ...
Jan 31, 2023
0
77
The U.S. Food and Drug Administration (FDA) has approved the targeted imaging agent Cytalux (pafolacianine) for use in lung cancer surgery. This injectable diagnostic binds to cancerous tissue and glows when stimulated by ...
Dec 17, 2022
0
79
